Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Morgensztern

Showing results (101-110 of 184) with videos related to

Pageof 19
Sort By:
Frontiers in Oncology|May 27, 2024
Incidence and risk factors for bone metastases at presentation in solid tumorsBrendan J Knapp, Giordano F Cittolin-Santos, Mary E Flanagan, et al.
Leukemia & Lymphoma|December 30, 2009
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphomaIzidore S Lossos, Peter J Hosein, Daniel Morgensztern, et al.
American Journal of Clinical Oncology|December 17, 2015
Immunogenicity of Influenza Vaccination in Patients With CancerSaiama N Waqar, Leigh Boehmer, Daniel Morgensztern, et al.
Clinical Lung Cancer|March 13, 2018
Non-small-cell Lung Cancer With Brain Metastasis at PresentationSaiama N Waqar, Pamela P Samson, Cliff G Robinson, et al.
Journal of Thoracic Disease|July 10, 2024
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancerChristine Auberle, Feng Gao, Mark Sloan, et al.
Journal of Thoracic Disease|August 23, 2021
A phase II study of everolimus in patients with advanced solid malignancies with <i>TSC1, TSC2, NF1, NF2</i> or <i>STK11</i> mutationsSiddhartha Devarakonda, Bruna Pellini, Luke Verghese, et al.
The Annals of Thoracic Surgery|January 24, 2017
Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung CancerPamela Samson, Traves D Crabtree, Cliff G Robinson, et al.
Chest|November 29, 2012
Use of new treatment modalities for non-small cell lung cancer care in the Medicare populationMichael T Vest, Jeph Herrin, Pamela R Soulos, et al.
American Journal of Clinical Oncology|September 12, 2015
Brain Metastases at Presentation in Patients With Non-Small Cell Lung CancerSaiama N Waqar, Sadaf H Waqar, Kathryn Trinkaus, et al.
The Annals of Thoracic Surgery|March 4, 2014
Treating locally advanced disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data BaseAmy C Moreno, Daniel Morgensztern, Daniel J Boffa, et al.
Pageof 19

Showing results (101-110 of 184) with videos related to

Sort By:
Pageof 19
Frontiers in Oncology|May 27, 2024
Incidence and risk factors for bone metastases at presentation in solid tumorsBrendan J Knapp, Giordano F Cittolin-Santos, Mary E Flanagan, et al.
Leukemia & Lymphoma|December 30, 2009
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphomaIzidore S Lossos, Peter J Hosein, Daniel Morgensztern, et al.
American Journal of Clinical Oncology|December 17, 2015
Immunogenicity of Influenza Vaccination in Patients With CancerSaiama N Waqar, Leigh Boehmer, Daniel Morgensztern, et al.
Clinical Lung Cancer|March 13, 2018
Non-small-cell Lung Cancer With Brain Metastasis at PresentationSaiama N Waqar, Pamela P Samson, Cliff G Robinson, et al.
Journal of Thoracic Disease|July 10, 2024
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancerChristine Auberle, Feng Gao, Mark Sloan, et al.
Journal of Thoracic Disease|August 23, 2021
A phase II study of everolimus in patients with advanced solid malignancies with <i>TSC1, TSC2, NF1, NF2</i> or <i>STK11</i> mutationsSiddhartha Devarakonda, Bruna Pellini, Luke Verghese, et al.
The Annals of Thoracic Surgery|January 24, 2017
Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung CancerPamela Samson, Traves D Crabtree, Cliff G Robinson, et al.
Chest|November 29, 2012
Use of new treatment modalities for non-small cell lung cancer care in the Medicare populationMichael T Vest, Jeph Herrin, Pamela R Soulos, et al.
American Journal of Clinical Oncology|September 12, 2015
Brain Metastases at Presentation in Patients With Non-Small Cell Lung CancerSaiama N Waqar, Sadaf H Waqar, Kathryn Trinkaus, et al.
The Annals of Thoracic Surgery|March 4, 2014
Treating locally advanced disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data BaseAmy C Moreno, Daniel Morgensztern, Daniel J Boffa, et al.
Pageof 19